^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CD20 positive

    i
    Other names: CD20, MS4A1, Membrane Spanning 4-Domains A1, Membrane-Spanning 4-Domains, Subfamily A, Member 1, Leukocyte Surface Antigen Leu-16, B-Lymphocyte Antigen CD20, CD20 Antigen, Membrane-Spanning 4-Domains Subfamily A Member 1, B-Lymphocyte Cell-Surface Antigen B1, B-Lymphocyte Surface Antigen B1, CD20 Receptor, LEU-16, CVID5, MS4A2
    Entrez ID:
    494216
    Related biomarkers:
    Expression
    Others
    1d
    ROMA: Rituximab Maintenance Versus Observation After R2 Induction in Previously Untreated Marginal Zone Lymphoma (clinicaltrials.gov)
    P2, N=144, Not yet recruiting, Sun Yat-sen University
    New P2 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • lenalidomide
    1d
    Identification of prognostic immune-related genes and evaluation of chemotherapy and immunotherapy responses in pancreatic cancer. (PubMed, Transl Cancer Res)
    Importantly, findings from the clinical cohort confirmed that ITGA3 expression was positively correlated with CD206 and PD-L1, and negatively correlated with CD8 and CD19, supporting its role in shaping an immunosuppressive microenvironment. ITGA3 is a promising immune-related biomarker for predicting prognosis and therapeutic response in PDAC and may provide a potential target for personalized treatment strategies.
    Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8) • MRC1 (Mannose Receptor C-Type 1) • ITGA3 (Integrin Subunit Alpha 3)
    |
    PD-L1 expression • CD20 positive • PD-L1 negative
    2d
    AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study") (clinicaltrials.gov)
    P1, N=15, Not yet recruiting, National Cancer Institute (NCI)
    New P1 trial
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • CD4 (CD4 Molecule)
    |
    CD20 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • Truxima (rituximab-abbs) • Columvi (glofitamab-gxbm) • Mabtas (rituximab biosimilar)
    2d
    ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies (clinicaltrials.gov)
    P1, N=42, Active, not recruiting, Acepodia Biotech, Inc. | Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2025 --> Jul 2026
    Enrollment closed • Trial primary completion date • First-in-human
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Gazyva (obinutuzumab) • cyclophosphamide • fludarabine IV • ACE1831
    2d
    Association between CD79B expression and polatuzumab vedotin efficacy, and therapy-induced changes in CD79B expression in diffuse large B-cell lymphoma. (PubMed, Virchows Arch)
    Among 24 patients with recurrent tumor biopsies, 13% showed loss of/decreased CD79B expression. In conclusion, immunohistochemical CD79B expression was not significantly associated with PV-containing therapy efficacy, which remained effective even in DLBCL with low CD79B expression.
    Journal
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD79B (CD79b Molecule) • IRF4 (Interferon regulatory factor 4) • MME (Membrane Metalloendopeptidase)
    |
    CD20 positive • CD20 negative
    |
    Polivy (polatuzumab vedotin-piiq)
    3d
    NCI-2024-00209: A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma (clinicaltrials.gov)
    P2, N=40, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Jan 2027 --> Jul 2027 | Trial primary completion date: Jan 2027 --> Jul 2027
    Trial completion date • Trial primary completion date
    |
    CD20 positive
    |
    Gazyva (obinutuzumab) • Yescarta (axicabtagene ciloleucel) • Tecartus (brexucabtagene autoleucel) • Columvi (glofitamab-gxbm)
    3d
    Primary central nervous system lymphoma and tumefactive demyelinating lesions in multiple sclerosis: a retrospective observational cohort study. (PubMed, Front Oncol)
    IL-6 and IL-10 levels was higher in the CSF of PCNSL than TDLs. Careful and comprehensive evaluation of clinical, neuroimaging, and pathological features, and CSF IL-6 and IL-10 levels facilitates the differential diagnosis betweenPCNSL and TDLs.
    Observational data • Retrospective data • Journal
    |
    CD20 (Membrane Spanning 4-Domains A1) • IL6 (Interleukin 6) • IL10 (Interleukin 10)
    |
    CD20 positive
    6d
    Management of Rituximab-Associated Hypersensitivity Reactions with Successfully Applied Desensitization Protocols: A Clinical Experience of 46 Infusions in 11 Patients. (PubMed, J Clin Med)
    Although the number of patients was limited, our findings indicate that in patients with hematologic malignancies receiving rituximab who develop early HSRs, desensitization represents a safe and effective strategy before considering treatment modification. These results support that, in appropriately selected patients, desensitization protocols are an important approach to continue therapy without interruption while minimizing adverse reactions.
    Journal
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab)
    6d
    Epcoritamab monotherapy or epcoritamab with lenalidomide as first-line therapy for patients with diffuse large B-cell lymphoma (EPCORE DLBCL-3): primary analysis of an open-label, multicentre, randomised, phase 2 trial. (PubMed, Lancet Haematol)
    Fixed-duration epcoritamab monotherapy showed promising complete response rates and a manageable safety profile in older adults with newly diagnosed DLBCL and comorbidities, with slight differences between stages 1 and 2. Continued investigation of epcoritamab as a first-line chemotherapy-free treatment option is warranted.
    P2 data • Journal
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    lenalidomide • Epkinly (epcoritamab-bysp)
    7d
    Non-classical immune checkpoint CD137/CD137L and CD200/CD200R expressions are regulated by the tumor immune microenvironment in lymph node aspirates from lung cancer patients. (PubMed, Front Immunol)
    CD137/CD137L and CD200/CD200R interact with PD-1-related pathways in metastatic LNs, forming an integrated immunoregulatory network predominantly shaped at the tumor cell level. Flow cytometric analysis of LN aspirates may help identify additional therapeutic targets in lung cancer.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • PD-L2 (Programmed Cell Death 1 Ligand 2) • TNFRSF9 (TNF Receptor Superfamily Member 9) • CD200 (CD200 Molecule) • CD200R1 (CD200 Receptor 1)
    |
    PD-L1 expression • CD20 positive
    8d
    A clinical trial of MK-1045 and rituximab in people with follicular lymphoma (MK-1045-007) (2025-522777-10-00)
    P2/3, N=2, Not yet recruiting, Merck Sharp & Dohme LLC
    New P2/3 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • bendamustine • Truxima (rituximab-abbs) • Actemra IV (tocilizumab)
    9d
    Pola-R-CHP Plus Sonrotoclax in Untreated BCL2-High/Double-Hit LBCL (clinicaltrials.gov)
    P1/2, N=40, Not yet recruiting, Ruijin Hospital
    New P1/2 trial • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • prednisone • Polivy (polatuzumab vedotin-piiq) • Beqalzi (sonrotoclax)